HDAC6: Tumor Progression and Beyond.
1/5 보강
Histone Deacetylase 6 (HDAC6) is an intriguing therapeutic target in cancer research, distinguished as the only HDAC family member predominantly located in the cytoplasm.
APA
Oliveira-Silva JM, de Oliveira LS, et al. (2026). HDAC6: Tumor Progression and Beyond.. Current cancer drug targets, 26(1), 47-63. https://doi.org/10.2174/0115680096332732241113053459
MLA
Oliveira-Silva JM, et al.. "HDAC6: Tumor Progression and Beyond.." Current cancer drug targets, vol. 26, no. 1, 2026, pp. 47-63.
PMID
39781719 ↗
Abstract 한글 요약
Histone Deacetylase 6 (HDAC6) is an intriguing therapeutic target in cancer research, distinguished as the only HDAC family member predominantly located in the cytoplasm. HDAC6 features two catalytic domains and a unique ubiquitin-binding domain, which sets it apart from other HDACs. Beyond its role in histone deacetylation, HDAC6 targets various nonhistone substrates, such as α-tubulin, cortactin, Heat Shock Protein 90 (HSP90), and Heat Shock Factor 1 (HSF1). Its involvement spans critical aspects of tumor progression, including invasion, metastasis, angiogenesis, drug resistance, stemness, and the reduction of tumor cell immunogenicity. Given these functions, HDAC6 inhibitors are emerging as valuable tools in the treatment of both solid and hematological tumors. Recent advancements have seen several HDAC6 inhibitors to enter clinical trials, with promising outcomes reported. This review covers the structural features of HDAC6, its biological roles, and its impact on tumor development, particularly focusing on progression-related events. Additionally, a detailed discussion of preclinical and clinical trials involving selective HDAC6 inhibitors is provided.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.